Journal
CLINICAL AND EXPERIMENTAL MEDICINE
Volume 5, Issue 4, Pages 135-140Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10238-005-0079-y
Keywords
intravenous immunoglobulin; autoimmune disorders; inflammatory diseases; mechanisms
Categories
Ask authors/readers for more resources
Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over two decades. Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki syndrome, and the prevention of graft versus host disease in recipients of allogeneic bone marrow transplants. Its use has also been reported in a large number of other autoimmune and systemic inflammatory conditions. In this review, we discuss the mechanisms by which IVIg exerts immunomodulatory effects in immune pathologies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available